Search Results - "N. A. Avxentyev"

Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable BRAF V600-mutated metastatic melanoma in Russia by Avxentyev, N. A., Makarova, Yu. V.

“…Objective : to perform a cost-effectiveness analysis of using encorafenib and binimetinib combination in the first-line therapy for metastatic or unresectable…”
Get full text

Modeling the impact of using trastuzumab deruxtecan in patients with breast cancer on reducing cancer mortality in Russia by Avxentyev, N. A., Makarova, Yu. V., Makarov, A. S.

“…Background. Reducing malignant mortality to 185 cases per 100,000 by 2030 is one of goals of the state program “Healthcare development” in Russia. Aim. To…”
Get full text

Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation by Avxentyev, N. A., Makarova, Yu. V.

“…Background. Diabetic nephropathy (DN) is a specific kidney lesion in patients with diabetes mellitus, which leads to the development of endstage kidney disease…”
Get full text

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review by Avxentyev, N. A., Andreyashkina, I. I., Artamonova, E. V., Bolotina, L. V., Kovalenko, E. I., Sisigina, N. N.

“…At present, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors such as palbociclib, ribociclib, and abemaciclib are widely used for the first-line treatment…”
Get full text

Estimating long-term overall survival with olaparib as maintenance therapy in patients with newly diagnosed advanced ovarian cancer with BRCA mutations by Avxentyev, N. A., Khokhlova, S. V., Frolov, M. Yu, Makarov, A. S.

“…Background. According to randomized clinical trial SOLO1 olaparib statistically significantly improves progression-free survival versus placebo as a…”
Get full text

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer by Avxentyev, N. A., Lubennikova, E. V., Frolov, M. Yu

“…Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors palbociclib, ribociclib and abemaciclib are the new treatment options for postmenopausal women with locally…”
Get full text

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma by Avxentyev, N. A., Pazuhina, E. M., Tumyan, G. S., Zeynalova, P. A.

“…Background . In the Russian Federation, in 2018 3,207 new cases of Hodgkin’s lymphoma (HL) were detected, mainly in adults. Despite significant advances in the…”
Get full text

Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia by Avxentyev, N. A., Frolov, M. Yu, Makarov, A. S.

“…Ilmatinib is currently the most widely used tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML) in Russia. When patients develop…”
Get full text

Pharmacoeconomic analysis of everolimus immunosuppressive therapy for de novo kidney transplant recipients in Russia by N. A. Avxentyev, E. V. Derkach, E. I. Prokopenko

“…Currently, patients after kidney transplantation can receive mycophenolate mofetil (MPM), mycophenolic acid (MPA), cyclosporine (CSA) and tacrolimus (TAC)…”
Get full text

PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA by Avxentyev, N. A., Frolov, M. Yu

“…The aim of the current study is pharmacoeconomic evaluation of using combined drug Vesomni (controlled release tablets tamsulosin 0.4 mg + solifenacin 6 mg)…”
Get full text

Pharmacoeconomic Analysis Of Everolimus Immunosupressive Therapy After Renal Transplantation by Avxentyeva, M, Avxentyev, NA, Frolov, M, Derkach, EV

Get full text

METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY by Avxentyev, N. A., Derkach, E. V., Pyadushkina, E. A., Ter-Ovanesov, M. D.

“…Targeted drugs are recommended for treatment of metastatic colorectal cancer. Second and further lines therapy options include anti-EGFR therapy, eligible for…”
Get full text

Costs Of Overactive Bladder Symptoms Treatment With Solifenacin by Avxentyeva, M, Gerasimova, K, Khachatryan, GR, Frolov, M, Avxentyev, NA, Pyadushkina, E

Get full text

Expanding the usage of osimertinib as adjuvant therapy for EGFR-mutated NSCLC: a model-based assessment of its impact on reducing cancer mortality in Russia by Avxentyev, N. A., Makarov, A. S., Sisigina, N. N.

“…Introduction . Platinum-based chemo have long been the only option for adjuvant therapy after tumor resection in early-stage NSCLC. Osimertinib is EGFR…”
Get full text

EE402 Social and Economic Burden of Breast Cancer in Russia by Avxentyev, NA, Makarova, Y

Get full text

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer by N. A. Avxentyev, A. S. Makarov, M. Yu. Frolov

“…Introduction. A number of drugs, which improve overall survival and quality of patients’ life, became available for treatment of metastatic…”
Get full text

EE676 Impact of Using Innovative Antineoplastic Drugs on Cancer Mortality in Russia by Avxentyev, NA, Sisigina, N, Frolov, M, Makarov, A

Get full text

EE539 Social and Economic Burden of HIV in Russia by Avxentyev, NA, Avxentyeva, M, Makarov, A, Makarova, Y

Get full text

EE404 Forecast of Social and Economic Burden of HIV-Infection in Russia in Different Scenarios of Anti-HIV Policy up to 2035 by Avxentyev, NA, Avxentyeva, M, Makarov, A, Makarova, Y

Get full text

PCN137 - Pharmacoeconomic Analysis of Enzalutamide and Abiraterone for Treatment of Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer by Avxentyev, NA, Frolov, M

Get full text